Erick de la Cruz‐Hernandez

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer

Claudia Arce, Carlos Pérez‐Plasencia, Aurora González‐Fierro et al. · PLoS ONE · 2006 · 144 citations · Full text

Medicine, Oncology, Pharmacology +16

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

Jaime Coronel, Lucely Cetina, Irlanda Pacheco et al. · Medical Oncology · 2010 · 132 citations

Medicine, Oncology, Pharmacology +15

E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway

Adriana Contreras‐Paredes, Erick de la Cruz‐Hernandez, Imelda Martínez-Ramírez et al. · Virology · 2008 · 94 citations

Life Sciences, Molecular Biology, Oncology +16

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

María de Lourdes Mora‐García, Alfonso Dueñas‐González, Jorge Hernández‐Montes et al. · Journal of Translational Medicine · 2006 · 73 citations · Full text

Medicine, Immunology, Oncology +17

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

Myrna Candelaria, Aquileo Herrera, Juan Labardini et al. · Annals of Hematology · 2010 · 72 citations

Medicine, Pharmacology, Pharmacotherapy +8